Segment Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Information

Schedule of net product sales, cost of product sales and gross profit for each commercial products

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):

	Three Months Ended September 30,
2019	Remodulin		Tyvaso		Orenitram		Unituxin		Adcirca		Total
Net product sales	$	168.3	$	110.8	$	62.0	$	30.1	$	30.3	$	401.5
Cost of product sales		5.5		6.9		3.5		4.1		13.0		33.0
Gross profit	$	162.8	$	103.9	$	58.5	$	26.0	$	17.3	$	368.5
2018
Net product sales	$	153.6	$	107.8	$	53.8	$	22.9	$	74.6	$	412.7
Cost of product sales		4.4		6.9		3.9		4.2		32.5		51.9
Gross profit	$	149.2	$	100.9	$	49.9	$	18.7	$	42.1	$	360.8
	Nine Months Ended September 30,
2019	Remodulin		Tyvaso		Orenitram		Unituxin		Adcirca		Total
Net product sales	$	479.6	$	324.2	$	174.4	$	80.1	$	79.4	$	1,137.7
Cost of product sales		16.1		14.8		12.3		11.4		34.2		88.8
Gross profit	$	463.5	$	309.4	$	162.1	$	68.7	$	45.2	$	1,048.9
2018
Net product sales	$	439.9	$	308.3	$	155.5	$	60.7	$	282.0	$	1,246.4
Cost of product sales		10.8		14.3		9.9		9.9		121.9		166.8
Gross profit	$	429.1	$	294.0	$	145.6	$	50.8	$	160.1	$	1,079.6

Schedule of net revenues from external customers by geographic area

Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	359.4	$	389.0	$	1,028.4	$	1,177.1
Rest-of-World(1)		42.1		23.7		109.3		69.3
Total	$	401.5	$	412.7	$	1,137.7	$	1,246.4

(1) Primarily Europe.

Schedule of revenue from two specialty pharmaceutical distributors in the United States as a percentage of total revenue

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Distributor 1	53	%	52	%	55	%	50	%
Distributor 2	21	%	18	%	21	%	17	%